Luke Russell

909 total citations
19 papers, 648 citations indexed

About

Luke Russell is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Luke Russell has authored 19 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Luke Russell's work include Virus-based gene therapy research (13 papers), CAR-T cell therapy research (8 papers) and Herpesvirus Infections and Treatments (4 papers). Luke Russell is often cited by papers focused on Virus-based gene therapy research (13 papers), CAR-T cell therapy research (8 papers) and Herpesvirus Infections and Treatments (4 papers). Luke Russell collaborates with scholars based in United States, Qatar and China. Luke Russell's co-authors include Kah-Whye Peng, Balveen Kaur, Stephen J. Russell, Ji Young Yoo, Kah Whye Peng, Rosa María Díaz, Michael A. Caligiuri, Jianhua Yu, Yeshavanth Banasavadi‐Siddegowda and Chelsea Bolyard and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Luke Russell

18 papers receiving 646 citations

Peers

Countries citing papers authored by Luke Russell

Since Specialization

Citations

This map shows the geographic impact of Luke Russell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Russell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Russell more than expected).

Fields of papers citing papers by Luke Russell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Russell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Russell. The network helps show where Luke Russell may publish in the future.

Co-authorship network of co-authors of Luke Russell

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Russell. A scholar is included among the top collaborators of Luke Russell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Russell. Luke Russell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies. 2023 ·Journal of Clinical Oncology ·Kah Whye Peng, (unknown), (unknown), Joselle Cook, Lianwen Zhang, Thomas E. Witzig, Javier Muñoz, Stephen M. Broski, Susan M. Geyer, Brenda Ginos, Luke Russell, Alice Bexon, Stephen J. Russell, Martha Q. Lacy	1
2	The 13th International Oncolytic Virus Conference: Powerful payloads gain clinical momentum 2022 ·Molecular Therapy ·Shruthi Naik, Luke Russell	4
3	Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo 2021 ·Molecular Therapy — Oncolytics ·Jayeeta Ghose, (unknown), Mariam Murtadha, Emine Gulsen Gunes, Enrico Caserta, Ji Young Yoo, Luke Russell, Alena Cristina Jaime‐Ramirez, Benjamin G. Barwick, Vikas A. Gupta, James F. Sanchez, Douglas W. Sborov, Steven T. Rosen, Amrita Krishnan, Lawrence Boise, Balveen Kaur, Craig C. Hofmeister, Flavia Pichiorri	10
4	505 Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1–2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors 2021 ·SHILAP Revista de lepidopterología ·Manish R. Patel, Steven Powell, James Strauss, Melissa L. Johnson, Timothy P. Cripe, Kah-Whye Peng, Stephen J. Russell, Luke Russell, Monica Reckner, Erol Wiegert, Alice Bexon, Jaime R. Merchan	1
5	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors. 2020 ·Journal of Clinical Oncology ·Jaime R. Merchan, Manish R. Patel, Timothy P. Cripe, Matthew Old, James Strauss, (unknown), Rosa María Díaz, Kah Whye Peng, Stephen J. Russell, Luke Russell, Monica Reckner, Erol Wiegert, Alice Bexon, Steven Powell	12
6	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma. 2020 ·Journal of Clinical Oncology ·Mario Sznol, Jose Lutzky, Alex A. Adjei, Steven Powell, Aiwu Ruth He, Manish R. Patel, Steven O’Day, Naimish Pandya, (unknown), Monica Reckner, (unknown), Rosa María Díaz, Luke Russell, Kah Whye Peng, Erol Wiegert, Giuseppe Gullo, Frank Seebach, Israel Lowy, Alice Bexon	1
7	Oncolytic Viruses: Priming Time for Cancer Immunotherapy 2019 ·BioDrugs ·Luke Russell, Kah Whye Peng, Stephen J. Russell, Rosa María Díaz	104
8	Correction: Amendments: Publisher Correction: An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma 2019 ·Nature Biotechnology ·(unknown), Rui Ma, Luke Russell, Ji Young Yoo, Jianfeng Han, Hanwei Cui, Ping Yi, Jianying Zhang, Hiroshi Nakashima, (unknown), E. Antonio Chiocca, Balveen Kaur, Michael A. Caligiuri, Jianhua Yu	9
9	PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance 2018 ·Nature Communications ·Luke Russell, Jessica Swanner, Alena Cristina Jaime‐Ramirez, Yufeng Wang, (unknown), Yeshavanth Banasavadi‐Siddegowda, Ji Young Yoo, Gina M. Sizemore, Raleigh D. Kladney, Jianying Zhang, Norman L. Lehman, Michael C. Ostrowski, Bangxing Hong, Michael A. Caligiuri, Jianhua Yu, Balveen Kaur	55
10	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma 2018 ·Nature Biotechnology ·Bo Xu, Rui Ma, Luke Russell, Ji Young Yoo, Jianfeng Han, Hanwei Cui, Ping Yi, Jianying Zhang, Hiroshi Nakashima, (unknown), E. Antonio Chiocca, Balveen Kaur, Michael A. Caligiuri, Jianhua Yu	66
11	The emerging role of oncolytic virus therapy against cancer 2018 ·Chinese Clinical Oncology ·Luke Russell, Kah-Whye Peng	100
12	Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema 2018 ·Molecular Therapy — Oncolytics ·Bangxing Hong, Kamaldeen Muili, Chelsea Bolyard, Luke Russell, Tae Jin Lee, Yeshavanth Banasavadi‐Siddegowda, Ji Young Yoo, Yuanqing Yan, Leomar Y. Ballester, Kurt H. Bockhorst, Balveen Kaur	29
13	Abstract 49: Stromal platelet derived growth factor receptor (PDGFRβ) signaling: A novel therapeutic target for breast cancer brain metastasis (BCBM) 2018 ·Cancer Research ·Katie Thies, (unknown), Blake E. Hildreth, Luke Russell, Steven T. Sizemore, Anthony J. Trimboli, Raleigh D. Kladney, Chelsea Bolyard, Robert Pilarski, Lynn Schoenfield, José Javier Otero, Arnab Chakravarti, Matthew D. Ringel, Balveen Kaur, Gustavo Leone, Michael C. Ostrowski, Gina M. Sizemore	0
14	PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells 2016 ·Oncogene ·Yeshavanth Banasavadi‐Siddegowda, Luke Russell, (unknown), Vrajesh Karkhanis, Theresa Relation, Ji Young Yoo, J. Zhang, Saı̈d Sif, Jaime Imitola, Robert A. Baiocchi, Balveen Kaur	100
15	Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma 2016 ·Blood ·Jayeeta Ghose, Luke Russell, Enrico Caserta, Ramasamy Santhanam, Alena Cristina Jaime‐Ramirez, Domenico Viola, Amrita Krishnan, Craig C. Hofmeister, Balveen Kaur, Flavia Pichiorri	4
16	The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment 2015 ·Clinical Cancer Research ·Walter H. Meisen, Eric S. Wohleb, Alena Cristina Jaime‐Ramirez, Chelsea Bolyard, Ji Young Yoo, Luke Russell, Jayson Hardcastle, (unknown), Kamaldeen Muili, Jianhua Yu, Michael A. Caligiuri, Jonathan P. Godbout, Balveen Kaur	77
17	Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model 2015 ·Bulletin of Mathematical Biology ·(unknown), Luke Russell, Balveen Kaur, Avner Friedman	13
18	Role of Cysteine-rich 61 Protein (CCN1) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance 2014 ·Molecular Therapy ·Amy Haseley Thorne, Walter H. Meisen, Luke Russell, Ji Young Yoo, Chelsea Bolyard, Justin D. Lathia, Jeremy N. Rich, Vinay K. Puduvalli, Hsiaoyin Mao, Jianhua Yu, Michael A. Caligiuri, Susheela Tridandapani, Balveen Kaur	38
19	Faster Replication and Higher Expression Levels of Viral Glycoproteins Give the Vesicular Stomatitis Virus/Measles Virus Hybrid VSV-FH a Growth Advantage over Measles Virus 2014 ·Journal of Virology ·(unknown), Luke Russell, Stephen J. Russell, Kah-Whye Peng	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact